FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204264877> ?p ?o ?g. }

• W3204264877 endingPage "154" @default.
• W3204264877 startingPage "147" @default.
• W3204264877 abstract "To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy.In this prospective, adaptive, phase-2/3, open-label study (CTRI/2014/12/005234), patients were randomized (1:1:1) to three FDC doses (doses/day: D1, capecitabine + cyclophosphamide 1400 mg + 60 mg; D2, 1800 mg + 80 mg; D3, 2200 mg + 100 mg) for 14 days, in 21-day cycles. In Part-I, multiple-dose pharmacokinetics and optimal dose(s) were evaluated with futility analysis. Group(s) with <3 responders based on best overall response rate (BOR, complete response [CR]+partial response [PR]), were discontinued. Efficacy (BOR, disease control rates [DCR; CR + PR + stable disease]) and safety of optimal dose(s) were evaluated in Part-II.Of 66 patients (n = 22/group) in Part-I, pharmacokinetics (D1 = 7/22, D2 = 9/22, D3 = 8/22) showed dose-proportionality for cyclophosphamide and greater than dose-proportionality for capecitabine. Modified intent-to-treat (mITT) analysis showed BOR of 7.14% (1/14) in D1 (discontinued), and 22.22% (4/18) each in D2 and D3, respectively. In Part-II, 50 additional patients were randomized in D2 and D3 (n = 144; total 72 [22 + 50] patients/group). mITT analysis in D2 (n = 54) and D3 (n = 58) showed BOR of 29.63% (16/54, 95%CI: 17.45-41.81%) and 22.41% (13/58, 95%CI: 11.68-33.15%), respectively. DCR in D2 and D3 were 87.04% (47/54, 95%CI: 78.08-96.00%) and 82.76% (48/58; 95%CI: 73.04-92.48%) after 3 and 57.41% (31/54; 95%CI: 52.41-79.50%) and 50.00% (29/58; 95%CI: 40.40-67.00%), after 6-cycles, respectively. Hand-foot syndrome (16.67%), vomiting (9.72%) in D2, and hand-foot syndrome (18.06%), asthenia (15.28%) in D3 were most-common adverse events.FDC of capecitabine + cyclophosphamide (1800 + 80 mg/day) showed high disease control rates and good safety profile in MBC patients." @default.
• W3204264877 created "2021-10-11" @default.
• W3204264877 creator A5011923101 @default.
• W3204264877 creator A5016024500 @default.
• W3204264877 creator A5016745365 @default.
• W3204264877 creator A5027406846 @default.
• W3204264877 creator A5030082659 @default.
• W3204264877 creator A5030477675 @default.
• W3204264877 creator A5031382834 @default.
• W3204264877 creator A5032816080 @default.
• W3204264877 creator A5035929405 @default.
• W3204264877 creator A5041942429 @default.
• W3204264877 creator A5047135174 @default.
• W3204264877 creator A5058903725 @default.
• W3204264877 creator A5060565835 @default.
• W3204264877 creator A5065710121 @default.
• W3204264877 creator A5070408233 @default.
• W3204264877 creator A5071367529 @default.
• W3204264877 creator A5074361800 @default.
• W3204264877 creator A5074545174 @default.
• W3204264877 creator A5090511457 @default.
• W3204264877 date "2021-12-01" @default.
• W3204264877 modified "2023-09-27" @default.
• W3204264877 title "Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study" @default.
• W3204264877 cites W1984750597 @default.
• W3204264877 cites W1985977793 @default.
• W3204264877 cites W2033274910 @default.
• W3204264877 cites W2038563885 @default.
• W3204264877 cites W2043457250 @default.
• W3204264877 cites W2048982965 @default.
• W3204264877 cites W2061444118 @default.
• W3204264877 cites W2069363844 @default.
• W3204264877 cites W2080436266 @default.
• W3204264877 cites W2090365682 @default.
• W3204264877 cites W2097249420 @default.
• W3204264877 cites W2112163451 @default.
• W3204264877 cites W2117094074 @default.
• W3204264877 cites W2133717560 @default.
• W3204264877 cites W2138537138 @default.
• W3204264877 cites W2144344664 @default.
• W3204264877 cites W2209470634 @default.
• W3204264877 cites W2218543387 @default.
• W3204264877 cites W2564988565 @default.
• W3204264877 cites W2800764403 @default.
• W3204264877 cites W2969746669 @default.
• W3204264877 doi "https://doi.org/10.1016/j.breast.2021.09.012" @default.
• W3204264877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8503662" @default.
• W3204264877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34624757" @default.
• W3204264877 hasPublicationYear "2021" @default.
• W3204264877 type Work @default.
• W3204264877 sameAs 3204264877 @default.
• W3204264877 citedByCount "0" @default.
• W3204264877 crossrefType "journal-article" @default.
• W3204264877 hasAuthorship W3204264877A5011923101 @default.
• W3204264877 hasAuthorship W3204264877A5016024500 @default.
• W3204264877 hasAuthorship W3204264877A5016745365 @default.
• W3204264877 hasAuthorship W3204264877A5027406846 @default.
• W3204264877 hasAuthorship W3204264877A5030082659 @default.
• W3204264877 hasAuthorship W3204264877A5030477675 @default.
• W3204264877 hasAuthorship W3204264877A5031382834 @default.
• W3204264877 hasAuthorship W3204264877A5032816080 @default.
• W3204264877 hasAuthorship W3204264877A5035929405 @default.
• W3204264877 hasAuthorship W3204264877A5041942429 @default.
• W3204264877 hasAuthorship W3204264877A5047135174 @default.
• W3204264877 hasAuthorship W3204264877A5058903725 @default.
• W3204264877 hasAuthorship W3204264877A5060565835 @default.
• W3204264877 hasAuthorship W3204264877A5065710121 @default.
• W3204264877 hasAuthorship W3204264877A5070408233 @default.
• W3204264877 hasAuthorship W3204264877A5071367529 @default.
• W3204264877 hasAuthorship W3204264877A5074361800 @default.
• W3204264877 hasAuthorship W3204264877A5074545174 @default.
• W3204264877 hasAuthorship W3204264877A5090511457 @default.
• W3204264877 hasBestOaLocation W32042648771 @default.
• W3204264877 hasConcept C112705442 @default.
• W3204264877 hasConcept C121608353 @default.
• W3204264877 hasConcept C126322002 @default.
• W3204264877 hasConcept C126894567 @default.
• W3204264877 hasConcept C143998085 @default.
• W3204264877 hasConcept C168563851 @default.
• W3204264877 hasConcept C2775930923 @default.
• W3204264877 hasConcept C2776694085 @default.
• W3204264877 hasConcept C2776755627 @default.
• W3204264877 hasConcept C2776802502 @default.
• W3204264877 hasConcept C2777511904 @default.
• W3204264877 hasConcept C2777909004 @default.
• W3204264877 hasConcept C526805850 @default.
• W3204264877 hasConcept C530470458 @default.
• W3204264877 hasConcept C71924100 @default.
• W3204264877 hasConcept C90924648 @default.
• W3204264877 hasConceptScore W3204264877C112705442 @default.
• W3204264877 hasConceptScore W3204264877C121608353 @default.
• W3204264877 hasConceptScore W3204264877C126322002 @default.
• W3204264877 hasConceptScore W3204264877C126894567 @default.
• W3204264877 hasConceptScore W3204264877C143998085 @default.
• W3204264877 hasConceptScore W3204264877C168563851 @default.
• W3204264877 hasConceptScore W3204264877C2775930923 @default.
• W3204264877 hasConceptScore W3204264877C2776694085 @default.
• W3204264877 hasConceptScore W3204264877C2776755627 @default.

• next